News

Shorter colonoscopies tied to higher colorectal cancer rates

View on the News

The evidence is 'clear'

In this well-planned study by Dr. Shaukat and her colleagues, the authors retrospectively examined the association between an endoscopist’s mean withdrawal time, adenoma detection rate (ADR), and interval cancer rate by using data from a large community gastroenterology practice and a state cancer registry. Prior studies have examined the association between mean withdrawal time and ADR, and ADR and interval cancer, but no study has examined the association between withdrawal time (a process measure of colonoscopy quality) and interval cancer (an outcome measure of colonoscopy quality). In this study, the authors found a statistically significant association between mean withdrawal time and ADR, and mean withdrawal time and interval cancer. Specifically, for mean withdrawal times less than 8 minutes, lower withdrawal times were associated with higher rates of interval cancer. Compared to physicians with mean withdrawal times greater than 6 minutes, those with withdrawal times less than 6 minutes were 2.3 times more likely to have a patient develop an interval cancer. The authors did not find a statistically significant association between ADR and interval cancers, which they attributed to confounding related to the increased risk of cancer in populations with higher adenoma prevalence and the increased likelihood of early cancer detection related to more frequent surveillance examinations. These data provide clear evidence of a link between a modifiable physician characteristic (mean withdrawal time), a readily measurable intermediate outcome measure (ADR), and an important clinical outcome (interval cancer). Such data should prove useful to those who seek not only to measure, but also to improve, the quality of colonoscopy.

Dr. Sameer D. Saini is assistant professor of internal medicine at the University of Michigan Health System, Ann Arbor. He has no conflicts of interest.


 

FROM GASTROENTEROLOGY

References

Risk of interval colorectal cancer (CRC) more than doubled when average withdrawal times during routine colonoscopy were less than 6 minutes, investigators reported in the October issue of Gastroenterology.

The results reinforce current guidelines that set a withdrawal time of at least 6 minutes as a quality indicator for screening colonoscopy, said Dr. Aasma Shaukat at the Minneapolis Veterans Affairs Health Care System and her associates. “Focusing quality-improvement efforts on withdrawal time [less] than 6 minutes would likely have the most impact,” although rates of interval CRC were “lowest and relatively constant” when withdrawal times were at least 8 minutes, the investigators said.

©Eraxion/thinkstockphotos.com

Short scope withdrawal times are known to decrease adenoma detection rates, but their impact on risk of interval CRC had not been examined before, the investigators said. Their retrospective, multicenter, community-based study included 76,810 colonoscopies performed by 51 endoscopists in and near Minneapolis and St. Paul between 2004 and 2009. Follow-up time was 5.5 years or until cancer diagnosis (Gastroenterology 2015 June 5 [doi: 10.1053/j.gastro.2015.06.001]) .

Patients of endoscopists whose withdrawal times averaged less than 6 minutes had a 2.3-fold higher rate of interval CRC, compared with patients whose physicians took at least 6 minutes to withdraw the scope (incidence rate ratio, 2.3; 95% confidence interval, 1.5-3.4; P less than .0001), even after they had accounted for age, sex, and quality of preparation for colonoscopy, the researchers reported. Every extra minute of withdrawal time also led to a 3.6% rise in the chances of detecting an adenoma (95% CI, 2.4%-4.8%; P less than .0001). Physicians whose adenoma detection rates averaged at least 25% had somewhat lower interval CRC rates among their patients than did those whose adenoma detection rates (ADRs) were less than 25%, although the difference was not significant. Adjusting for ADRs also did not alter the link between withdrawal time and risk of interval CRC, but restricting the analysis to 2007 and later weakened the association slightly (IRR, 2.0; 95% CI; 1.0-3.9; P = .04). Finally, patients who were aged 60-69 years had interval CRCs almost three times more often than did younger patients, and patients who were at least 70 years old had 6.2 times the frequency of interval CRCs, compared with the youngest age group, the investigators reported.The researchers designed the study around the 6-minute withdrawal time threshold because of current guidelines but found “no obvious cut point for defining poor quality for screening colonoscopies,” they said. Although the patient sample represented the community-based target population for screening programs, the study had some limitations, the investigators added. For example, they used 2007 withdrawal times for the years 2004-2006 because they lacked data for those years, and as a result, they could have overestimated the association between withdrawal time and risk of interval CRC, they said. They also would have missed any cancer cases diagnosed in other states and could not distinguish between cancers diagnosed because of symptoms and those that were first detected on screening colonoscopy, they noted.

A Veterans Affairs Career Development program and the Center for Chronic Disease Outcomes Research funded the study. The authors reported having no conflicts of interest.

Recommended Reading

WCD: Look for TNF inhibitor–induced psoriasis in kids
MDedge Family Medicine
Methotrexate ups risk of liver abnormalities, but not serious hepatic events
MDedge Family Medicine
Sofosbuvir-velpatasvir combo effective in all HCV genotypes
MDedge Family Medicine
ICAAC: GI PCR test helped infection control in a children’s hospital
MDedge Family Medicine
Readmissions for C. difficile infections high among elderly
MDedge Family Medicine
Sitting time linked to NAFLD
MDedge Family Medicine
ICAAC: Synergistic effects of two pediatric vaccines highlighted
MDedge Family Medicine
ECC: Nivolumab, Cabozantinib bring long overdue options to advanced kidney cancer
MDedge Family Medicine
ESC: New support for aspirin’s anticancer effect
MDedge Family Medicine
PCORI approves $83 million for HCV, rare disease research
MDedge Family Medicine